Focus on human microbiome to fight liver cirrhosis

22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to acute-on-chronic liver failure (ACLF), and a patient’s individual treatment response. Based on such biomarkers, we strive to develop novel diagnostic tools for earlier and better patient stratification and to establish personalised and effective treatment strategies.

Learn more

MICROB-PREDICT at EASL Congress 2023

Join us for a MICROB-PREDICT and DECISION networking event on 21st June, 13.30-14.30h at the EASL Congress Vienna, community hub. Learn about latest results and meet the team!

More news

MICROB-PREDICT 10th SC Meeting - Save the Date!

We are pleased to announce the upcoming 10th Steering Committee Meeting, hosted at the University of Münster, September 25-27, 2023. Find more information here.

More events
Follow us